GSK’s Exdensur receives Japan’s MHLW approval for severe asthma and chronic rhinosinusitis with nasal polyps: London, UK Wednesday, January 7, 2026, 10:00 Hrs [IST] GSK plc an ...

The longtime co-anchor isn't the only familiar face to have successful vocal cord surgery. Guthrie's TODAY colleague, ...

GSK has secured approval in Japan for Exdensur (depemokimab), the country’s first ultra-long-acting biologic for severe asthma and chronic rhinosinusitis with nasal polyps. Approved by Japan’s ...

A systematic review found improved sleep quality and longer REM sleep after endoscopic surgery for chronic rhinosinusitis ...

Dupilumab, a fully human monoclonal antibody, inhibits the signaling of the interleukin 4 (IL-4) and IL-13 pathways.

Treatments known as biologics - which work by switching off the immune system reaction that drives inflammation - are on the cusp of wider use for patients with severe chronic rhinosinusitis.

ABSTRACT: Background: Nasal polyposis causes significant morbidity worldwide, often requiring surgery when refractory to medical therapy. While Functional Endoscopic Sinus Surgery (FESS) is considered ...

Findings showed treatment with tezepelumab significantly reduced the size of nasal polyps and nasal congestion compared with placebo. The Food and Drug Administration (FDA) has approved Tezspire ® ...

Tezepelumab-ekko is now approved for chronic rhinosinusitis with nasal polyps (CRSwNP), targeting thymic stromal lymphopoietin and marking its second indication after severe asthma. The phase 3 ...

Approval broadens indication for TEZSPIRE to a second disease characterized by epithelial-driven inflammation WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca and Amgen’s TEZSPIRE® (tezepelumab -ekko) ...

Approval broadens indication for TEZSPIRE to a second disease characterized by epithelial-driven inflammation AstraZeneca and Amgen’s TEZSPIRE® (tezepelumab -ekko) has been approved in the US for the ...